Table 3.

Adverse Events and Discontinuations, According to Antiretroviral Regimen.^*

Event	EFV–FTC–TDF (N = 160)	RAL–FTC–TDF (N = 146)	RPV–FTC–TDF (N = 29)	All Patients (N = 335)
	number (percent)
Discontinuation of treatment owing to     adverse event	0	0	0	0
Death	0	1 (1)	0	1 (<1)
Any adverse event	125 (78)	114 (78)	18 (62)	257 (77)
Common adverse events†
Headache	41 (26)	38 (26)	4 (14)	83 (25)
Fatigue	41 (26)	26 (18)	4 (14)	71 (21)
Diarrhea	19 (12)	13 (9)	4 (14)	36 (11)
Nausea	17 (11)	13 (9)	3 (10)	33 (10)
Arthralgia	11 (7)	9 (6)	2 (7)	22 (7)
Upper respiratory tract infection	6 (4)	11 (8)	1 (3)	18 (5)
Vomiting	6 (4)	6 (4)	2 (7)	14 (4)
Muscle spasms	2 (1)	5 (3)	4 (14)	11 (3)
Constipation	5 (3)	3 (2)	2 (7)	10 (3)
Dysgeusia	5 (3)	1 (1)	2 (7)	8 (2)
Sinusitis	3 (2)	2 (1)	2 (7)	7 (2)
Serious adverse events
Any	4 (2)	3 (2)	1 (3)	8 (2)
Hepatocellular carcinoma	1 (1)	1 (1)	0	2 (1)
Portal-vein thrombosis	1 (1)	1 (1)	0	2 (1)
Arthralgia	1 (1)	0	0	1 (<1)
Azotemia	1 (1)	0	0	1 (<1)
Clostridium difficile colitis	0	1 (1)	0	1 (<1)
Cough	1 (1)	0	0	1 (<1)
Diarrhea	0	0	1 (3)	1 (<1)
Ileus	1 (1)	0	0	1 (<1)
Bacterial peritonitis	1 (1)	0	0	1 (<1)
Respiratory tract infection	0	1 (1)	0	1 (<1)
Sepsis	0	1 (1)	0	1 (<1)
Substance abuse	1 (1)	0	0	1 (<1)

^*EFV denotes efavirenz, FTC emtricitabine, RAL raltegravir, RPV rilpivirine, and TDF tenofovir disoproxil fumarate.

^†Listed are adverse events that were reported in at least 5% of patients in any group. Patients could have more than one adverse event or serious adverse event.